![Garth Cumberlidge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Garth Cumberlidge
Chief Executive Officer at SemaThera, Inc.
Profile
Garth Cumberlidge is the founder of Mimetogen Pharmaceuticals, Inc. which was founded in 2004.
He was the President & Chief Executive Officer from 2009 to 2010.
Currently, he is the President & Chief Executive Officer at SemaThera, Inc. since 2018.
Dr. Cumberlidge's former jobs include being the President & Chief Executive Officer at MP Biomedicals Canada ULC, Vice President-Worldwide Marketing & Sales at Bausch Health Americas, Inc., and Manager-European Sales & Marketing at Sigma Chemicals Co. He was also the Chairman at Eyevensys SAS from 2017 to 2020.
Dr. Cumberlidge's education includes an undergraduate degree from the University of London and a doctorate from the Max-Planck-Institute for Molecular Genetics.
Garth Cumberlidge active positions
Companies | Position | Start |
---|---|---|
SemaThera, Inc.
![]() SemaThera, Inc. BiotechnologyHealth Technology SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada. | Chief Executive Officer | 2018-10-31 |
Former positions of Garth Cumberlidge
Companies | Position | End |
---|---|---|
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Chairman | 2020-03-09 |
Sigma Chemicals Co.
![]() Sigma Chemicals Co. Chemicals: Major DiversifiedProcess Industries Sigma Chemicals Co. is an American company that manufactures chemicals. | Sales & Marketing | - |
MP Biomedicals Canada ULC
![]() MP Biomedicals Canada ULC Miscellaneous Commercial ServicesCommercial Services MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada. | Chief Executive Officer | - |
Bausch Health Americas, Inc.
![]() Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ. | Sales & Marketing | - |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Founder | - |
Training of Garth Cumberlidge
University of London | Undergraduate Degree |
Max-Planck-Institute for Molecular Genetics | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
Bausch Health Americas, Inc.
![]() Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ. | Health Technology |
MP Biomedicals Canada ULC
![]() MP Biomedicals Canada ULC Miscellaneous Commercial ServicesCommercial Services MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada. | Commercial Services |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Sigma Chemicals Co.
![]() Sigma Chemicals Co. Chemicals: Major DiversifiedProcess Industries Sigma Chemicals Co. is an American company that manufactures chemicals. | Process Industries |
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
SemaThera, Inc.
![]() SemaThera, Inc. BiotechnologyHealth Technology SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada. | Health Technology |
- Stock Market
- Insiders
- Garth Cumberlidge